TL;DR: Aetna, a CVS Health company, reaffirmed its position that epiretinal radiation therapy is experimental and not covered under CPB 0756, effective December 3, 2025. If your practice treats age-related macular degeneration and has ever billed — or considered billing — for this procedure, here's what changes for your billing team.

The Aetna epiretinal radiation therapy coverage policy under CPB 0756 Aetna system was modified on December 3, 2025. The policy covers CPT code 67036 and ICD-10 codes H35.30–H35.389, and it draws a hard line: this procedure does not meet medical necessity criteria for any indication. Claims will be denied. Full stop.


Quick-Reference Table

Field Detail
Payer Aetna, a CVS Health company
Policy Epiretinal Radiation Therapy
Policy Code CPB 0756
Change Type Modified
Effective Date December 3, 2025
Impact Level High — blanket non-coverage for all indications
Specialties Affected Ophthalmology, retinal surgery, radiation oncology
Key Action Audit any pending or recurring claims involving epiretinal radiation therapy before billing Aetna patients — denials are guaranteed

Aetna Epiretinal Radiation Therapy Coverage Criteria and Medical Necessity Requirements 2025

The short version: there are no coverage criteria. Aetna does not cover epiretinal radiation therapy under any clinical circumstances.

Under CPB 0756 Aetna system, the payer's position is that insufficient clinical evidence supports this treatment for age-related macular degeneration (AMD) or any other condition. That word "any" is doing a lot of work here. This isn't a narrow exclusion with carve-outs for certain patient populations or clinical protocols. It's a blanket denial.

From a medical necessity standpoint, Aetna will not recognize epiretinal radiation therapy as medically necessary regardless of diagnosis, provider documentation, or clinical rationale submitted. No amount of chart documentation will flip this to a covered service under the current policy.

This is the type of coverage policy that trips up ophthalmology billing teams who are tracking emerging AMD treatments and may see this procedure offered at academic centers or through investigational protocols. If a patient receives this treatment and you attempt to bill Aetna, expect a claim denial. The policy leaves no room for interpretation.

Prior authorization is not a path around this. Some billing teams assume that getting a prior auth approval creates a coverage obligation. That logic breaks down when the procedure is classified as experimental and investigational — prior authorization requests for non-covered services can still be denied, and an inadvertent approval doesn't guarantee payment. Don't rely on a prior auth to validate billing for epiretinal radiation therapy under Aetna.


Aetna Epiretinal Radiation Therapy Exclusions and Non-Covered Indications

Aetna classifies epiretinal radiation therapy as experimental, investigational, or unproven. That three-part label — experimental, investigational, or unproven — is intentional and consequential.

Each classification carries the same billing outcome: no reimbursement. But the language matters for appeals. "Experimental" and "investigational" often tie to clinical trial contexts. "Unproven" means the evidence base simply hasn't crossed the threshold Aetna requires for coverage. The policy uses all three terms together, which signals that Aetna is not leaving an opening for appeals based on arguing the procedure is "established in the literature."

The primary indication in scope here is age-related macular degeneration. AMD is the most common reason epiretinal radiation therapy would surface in a retina practice. Aetna explicitly calls it out, and then extends the non-coverage to "any other conditions" — a catch-all that covers off-label use as well.

For context, AMD treatment is a crowded coverage space. Aetna covers anti-VEGF injections under CPB 0701 (Vascular Endothelial Growth Factor Inhibitors for Ocular Indications). Photodynamic therapy with verteporfin is addressed under CPB 0594. Laser photocoagulation of drusen falls under CPB 0609. Epiretinal radiation therapy sits outside all of those covered pathways. It is not a billing alternative or complement to those treatments — it's a separate approach with its own non-coverage determination.

If your retina practice is billing Aetna for AMD treatment, audit your charge capture to confirm you're not inadvertently submitting epiretinal radiation codes. The exposure is real, particularly for practices that have recently added equipment or joined a clinical trial network.


Coverage Indications at a Glance

Indication Status Relevant Codes Notes
Age-related macular degeneration (AMD) Not Covered — Experimental/Investigational/Unproven CPT 67036; ICD-10 H35.30–H35.389 Blanket exclusion, no exceptions listed
Any other condition Not Covered — Experimental/Investigational/Unproven CPT 67036 Policy explicitly extends non-coverage beyond AMD to all indications

This policy is now in effect (since 2025-12-03). Verify your claims match the updated criteria above.

Aetna Epiretinal Radiation Therapy Billing Guidelines and Action Items 2025

This policy is clear enough that your action items are more about prevention than process. Here's what to do before and after the December 3, 2025 effective date.

#Action Item
1

Audit your charge master and charge capture templates now. Search for CPT 67036 and any associated charge descriptions tied to epiretinal radiation therapy. Flag any line items for review. If your practice doesn't perform this procedure, confirm it. If you do, move to step two.

2

Pull any pending Aetna claims that include CPT 67036 or ICD-10 codes H35.30–H35.389 in combination with radiation therapy documentation. Review them for accuracy before they go out. A claim that goes out after December 3, 2025 for this procedure will be denied.

3

Do not submit prior authorization requests for epiretinal radiation therapy as a coverage workaround. Prior auth doesn't create coverage for experimental procedures. A PA request that slips through does not obligate Aetna to pay, and it creates false confidence in your billing workflow.

+ 3 more action items

Enter your email to unlock all tables — 100% free

Unlocks every table on this page. Free weekly digest included. By subscribing you agree to our Terms and Privacy Policy.

The epiretinal radiation therapy billing risk here is straightforward: any claim you submit for this service to Aetna after December 3, 2025 is a guaranteed denial. The financial exposure depends on your payer mix and procedure volume, but even one or two denied claims per month adds up in write-offs, rework costs, and staff time. The fix is clean charge capture before claims go out.


Sample Version Diff Line-by-line changes
Previous VersionCurrent Version
Coverage is considered experimental and investigational for all indicationsCoverage is considered medically necessary when specific criteria are met
Prior authorization is not requiredPrior authorization is required for initial treatment
Documentation must include clinical historyDocumentation must include clinical history
+ 1 more action items

Enter your email to unlock all tables — 100% free

Unlocks every table on this page. Free weekly digest included. By subscribing you agree to our Terms and Privacy Policy.

CPT, HCPCS, and ICD-10 Codes for Epiretinal Radiation Therapy Under CPB 0756

CPT Codes Referenced in CPB 0756

Code Type Description Coverage Status
67036 CPT Vitrectomy, mechanical, pars plana approach Non-covered — listed as a related procedure code; epiretinal radiation therapy is classified experimental/investigational/unproven

A note on CPT 67036 specifically: this code describes a vitrectomy approach, not epiretinal radiation therapy as a standalone procedure. Aetna lists it under "Other CPT codes related to the CPB," which tells you something important. Epiretinal radiation therapy as delivered in clinical trials often involves a vitrectomy component to place the radiation device. If your surgical workflow involves both a vitrectomy and radiation delivery, both elements of that encounter sit inside this non-coverage determination. Don't assume the vitrectomy portion is separately billable when it's performed as part of the experimental radiation procedure.

Key ICD-10-CM Diagnosis Codes

Code Range Description
H35.30–H35.389 Degeneration of macula and posterior pole

This ICD-10 range covers the full spectrum of macular degeneration diagnoses, from unspecified degeneration of the macula (H35.30) through bilateral and laterality-specific codes within the H35.3 family. Any claim pairing a code from this range with documentation of epiretinal radiation therapy will trigger the non-coverage determination under CPB 0756.

If you're billing AMD-related services more broadly — anti-VEGF injections, laser treatment, diagnostic imaging — and a patient also received epiretinal radiation therapy at another facility, make sure your documentation clearly distinguishes the covered services from the non-covered procedure. Mixed-service claims can create unnecessary scrutiny.


Get the Full Picture for CPT 67036

Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.

🔍 Search by any code 🔔 Real-time alerts 📊 Line-by-line diffs ⏰ Deadline tracking
Get Full Access → $99/mo · 14-day money-back guarantee